Tuesday July 28, 2026
Section

KoreWire

Sarcomatrix Applies SarcoVista™ Translational Modeling to First-in-Human Dose Selection for S-969
Press Release

Sarcomatrix Applies SarcoVista™ Translational Modeling to First-in-Human Dose Selection for S-969

The preclinical-stage company is using its proprietary modeling platform to inform the starting dose and escalation

Read Full Story